Minocycline treatment in clinically isolated syndrome and serum NfL, GFAP, and metalloproteinase levels.

ABSTRACT:

Background

In the trial of Minocycline in Clinically Isolated Syndrome (MinoCIS), minocycline significantly reduced the risk of conversion to clinically definite multiple sclerosis (CDMS). Neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) are emerging biomarkers in MS, and minocycline modulates matrix metalloproteinases (MMPs).

Objective

To assess the value of blood NfL and GFAP as a biomarker of baseline and future disease activity and its utility to monitor treatment response in minocycline-treated patients with clinically isolated syndrome (CIS).

Methods

We measured NfL, GFAP, and MMPs in blood samples from 96 patients with CIS from the MinoCIS study and compared biomarkers with clinical and radiologic characteristics and outcome.

Result

SUBMITTER: Camara-Lemarroy C 

PROVIDER: S-EPMC9574233 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature